Boehringer Ingelheim: Diabetes Mellitus, Type 2 trials
The registry lists 130 Diabetes Mellitus, Type 2 studies with Boehringer Ingelheim as lead sponsor. 2 are open to participants now and 109 have results posted.
Phase 1 19Phase 2 18Phase 3 50Phase 4 9No phase 34(a study in two phases counts in both)
Studies
Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarRecruitingNCT07754461Phase 3
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseRecruitingNCT07064473Phase 3
- Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney DiseaseCompletedNCT05465317Results posted
- To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With EmpagliflozinCompletedNCT05162014Results posted
- Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes MellitusCompletedNCT05130463Results posted
- This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb AmputationsCompletedNCT04937816Results posted
- A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017CompletedNCT04927858Results posted
- A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 YearsCompletedNCT04531462Phase 4Results posted
- A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor AgonistsCompletedNCT04295005Results posted
- A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take InsulinCompletedNCT04233801Phase 3Results posted
- A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.CompletedNCT04153929Phase 2Results posted
- A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 DiabetesCompletedNCT04098575Results posted
- A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular OutcomesCompletedNCT03993132Results posted
- A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 DiabetesCompletedNCT03817463Results posted
- DIA_CENTRAL:T2D Treatment Pattern in Central EuropeCompletedNCT03807440Results posted
- Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and DehydrationCompletedNCT03764631Results posted
- A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 DiabetesCompletedNCT03761797Results posted
- Regulatory Request NIS in KoreaCompletedNCT03642717Results posted
- Empa PASS on Urinary Tract MalignanciesCompletedNCT03464045Results posted
- Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TMCompletedNCT03429543Phase 3Results posted
- Real World Glycemic Effectiveness of LinagliptinCompletedNCT03338803Results posted
- Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDVCompletedNCT03092752Results posted
- Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in ChinaCompletedNCT03064841Results posted
- Characteristics of Empagliflozin InitiatorsCompletedNCT03050619Results posted
- Linagliptin Add-on to Insulin Background TherapyCompletedNCT02897349Phase 3Results posted
- Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 InhibitorsCompletedNCT02864914Results posted
- JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes MellitusCompletedNCT02848833Results posted
- Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN StudyCompletedNCT02632747Phase 2Results posted
- Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02589639Phase 4Results posted
- Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RACompletedNCT02589626Phase 4Results posted
- Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02489968Phase 3Results posted
- Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02489942Results posted
- Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes MellitusCompletedNCT02453555Phase 3Results posted
- Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes MellitusCompletedNCT02367131Results posted
- Linagliptin as Add on to Basal Insulin in the ElderlyCompletedNCT02240680Phase 4Results posted
- Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of LinagliptinCompletedNCT02197078Results posted
- 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and HypertensionCompletedNCT02182830Phase 3Results posted
- Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic TherapyCompletedNCT02140645Results posted
- Oral and Non-insulin Injected Hypoglycemic Therapy Utilization PatternsCompletedNCT02138097Results posted
- Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes MellitusCompletedNCT02121483Phase 1Results posted
- Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01947855Phase 3Results posted
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 TabletsCompletedNCT01924767Phase 1Results posted
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal ImpairmentCompletedNCT01907113Phase 1Results posted
- PMS of Trazenta on the Long-term Use as Add-on TherapyCompletedNCT01904383Results posted
- A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in KoreaCompletedNCT01903356Results posted
- Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)CompletedNCT01897532Phase 4Results posted
- Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy ControlsCompletedNCT01867307Phase 2Results posted
- Linagliptin Among Filipino Patients With Type 2 Diabetes MellitusTerminatedNCT01826370Results posted
- MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptinCompletedNCT01792518Phase 3Results posted
- Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 DiabetesCompletedNCT01778049Phase 3Results posted
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01734785Phase 3Results posted
- Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 DiabetesCompletedNCT01719003Phase 3Results posted
- Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 PatientsCompletedNCT01708902Phase 3Results posted
- A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes MellitusCompletedNCT01707147Results posted
- Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)CompletedNCT01703286Phase 1Results posted
- Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes MellitusCompletedNCT01650259Results posted
- A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin TherapyCompletedNCT01649297Phase 2Results posted
- Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 DiabetesCompletedNCT01581658Phase 1Results posted
- Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 DiabetesCompletedNCT01512979Phase 4Results posted
- Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic ControlCompletedNCT01438814Phase 4Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsCompletedNCT01422876Phase 3Results posted
- Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin TabletCompletedNCT01383356Phase 1Results posted
- 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes MellitusCompletedNCT01370005Phase 3Results posted
- Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01368081Phase 3Results posted
- Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 DiabetesCompletedNCT01342484Phase 2Results posted
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes MellitusCompletedNCT01316341Phase 1Results posted
- Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes MellitusCompletedNCT01306214Phase 3Results posted
- Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesCompletedNCT01289990Phase 3Results posted
- Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 DiabetesCompletedNCT01276288Phase 1Results posted
- A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy SubjectsCompletedNCT01248364Phase 2Results posted
- CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesCompletedNCT01243424Phase 3Results posted
- Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin TherapyCompletedNCT01215097Phase 3Results posted
- Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic ControlCompletedNCT01214239Phase 3Results posted
- Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on BioavailabilityCompletedNCT01211197Phase 1Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With MetforminCompletedNCT01210001Phase 3Results posted
- Comprehensive Add on Study in JapanCompletedNCT01204294Phase 3Results posted
- Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-studyCompletedNCT01194830Phase 3Results posted
- Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01193218Phase 2Results posted
- 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 WeeksCompletedNCT01183013Phase 3Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01177813Phase 3Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 DiabetesCompletedNCT01167881Phase 3Results posted
- Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT01164501Phase 3Results posted
- Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01159600Phase 3Results posted
- BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).CompletedNCT01131676Phase 3Results posted
- Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal ImpairmentCompletedNCT01087502Phase 3Results posted
- Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 DiabetesCompletedNCT01084005Phase 3Results posted
- Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 DiabetesCompletedNCT01012037Phase 2Results posted
- Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT01011868Phase 2Results posted
- Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With PioglitazoneCompletedNCT00996658Phase 3Results posted
- Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00954447Phase 3Results posted
- Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic PatientsCompletedNCT00935220Phase 1Results posted
- Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg BidCompletedNCT00915772Phase 3Results posted
- 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)CompletedNCT00885118Phase 2Results posted
- Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label ExtensionCompletedNCT00881530Phase 2Results posted
- Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea DrugCompletedNCT00819091Phase 3Results posted
- Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background InclusiveCompletedNCT00800683Phase 3Results posted
- Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial DesignCompletedNCT00798161Phase 3Results posted
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic PatientsCompletedNCT00789035Phase 2Results posted
- BI 10773 add-on to Metformin in Patients With Type 2 DiabetesCompletedNCT00749190Phase 2Results posted
- A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is InappropriateCompletedNCT00740051Phase 3Results posted